Avillion names new CEO
This article was originally published in Scrip
Avillion, a drug development company focused on co-development and financing of late-stage pharmaceutical candidates from Phase III clinical development to marketing approval, has named Dr Allison Jeynes-Ellis chief executive officer. Dr Jeynes-Ellis is a founding member of Avillion's management team and was formerly the company's chief medical officer. She replaces Lewis Cameron who has "left the company to pursue other opportunities," Avillion said.